A carregar...
Tivozanib: a novel VGFR inhibitor for kidney cancer
Treatment of kidney cancer has changed over the past 10 years with the approval of several targeted agents. These drugs are given on a long term base and toxicity is an issue for most patients. Despite improvement compared to immunotherapy, most patients will progress on these drugs. There is a need...
Na minha lista:
| Publicado no: | Transl Androl Urol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4708224/ https://ncbi.nlm.nih.gov/pubmed/26816733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2223-4683.2012.07.04 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|